Page 1

November 9 , 2021 SG , Stevanato Group Stevanato Group Reports Strong Third Quarter 2021 Revenue and Financial Results and Updates Full Year 2021 Guidance PIOMBINO DESE , Italy -- ( BUSINESS WIRE ) -- Stevanato Group S.p.A. ( NYSE : STVN ) , a leading global provider of drug containment , drug delivery , and diagnostic solutions to the pharmaceutical , biotechnology , and life sciences industries , today announced its financial results for the third quarter 2021 . Third Quarter 2021 Highlights ( compared to the same period last year ) • Revenue grew 37 % to € 214.5 million driven by strong sales in both segments ; • Net profit totaled € 18.6 million and diluted EPS were € 0.07 , and both were tempered primarily by a discretionary , out - of - cycle bonus awarded to employees for their remarkable efforts over the last 18 months ; • Adjusted net profit increased 39 % to € 26.4 million ; and adjusted diluted EPS were € 0.10 • Adjusted EBITDA grew 33 % to € 51.4 million ; adjusted EBITDA margin was 24 % ; • Backlog increased to € 834 million ; and , • Based on year - to - date financial results and the visibility from backlog , the Company is increasing its revenue guidance and raising the bottom end of its ranges for adjusted diluted EPS and adjusted EBITDA . Third quarter revenue increased 37 % to € 214.5 million compared to the same period last year driven by strong sales in both segments . Gross profit increased 34 % to € 63.3 million , but gross profit margin of 29.5 % was tempered primarily by higher sales in the Engineering Segment which has a lower margin than the Biopharmaceutical and Diagnostics Solutions Segment . In the third quarter , the Company awarded a discretionary bonus of € 6.7 million to all staff to recognize their efforts over the past 18 months . The bonus was assumed in the Company's 2021 guidance provided in the second quarter of 2021. The bonus adversely impacted operating profit , net profit , and diluted earnings per share ( on a GAAP basis ) . In the third quarter , adjusted operating profit margin increased 80 basis points to 17 % , adjusted net profit increased 39 % to € 26.4 million , and adjusted diluted EPS were € 0.10 . As expected , approximately 16 % of third quarter 2021 revenue was attributable to Covid - 19 . In the third quarter , high value solutions accounted for approximately 23 % of consolidated revenue which was primarily due the rapid increase in revenue . This compares to 24 % in the prior - year period . Based on the current backlog , the Company expects a higher revenue contribution from high value solutions in the fourth quarter of 2021 in terms of overall dollar